A5010499363- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Glioma Diagnosis and Treatment
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Neuroblastoma Research and Treatments
- Cancer and Skin Lesions
- Cancer Genomics and Diagnostics
- Gastric Cancer Management and Outcomes
- Thyroid Cancer Diagnosis and Treatment
- Salivary Gland Tumors Diagnosis and Treatment
- Sarcoma Diagnosis and Treatment
- Brain Metastases and Treatment
- Cancer Treatment and Pharmacology
- Head and Neck Cancer Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Mechanisms and Therapy
- Breast Cancer Treatment Studies
- Cancer Research and Treatments
- Chromatin Remodeling and Cancer
- Meningioma and schwannoma management
- Neurofibromatosis and Schwannoma Cases
Eli Lilly (United States)
2012-2025
Loxo Oncology at Lilly (United States)
2024
Eli Lilly (India)
2014-2023
Eli Lilly (Singapore)
2023
National Taiwan University Hospital
2017
Eli Lilly (Japan)
2016
Guangzhou Medical University
2016
All India Institute of Medical Sciences
2005-2015
Maulana Azad Medical College
2004
To determine whether the addition of pemetrexed to gefitinib (P+G) provides clinical benefit, compared with monotherapy, in patients advanced nonsquamous (NS) non-small-cell lung cancer (NSCLC) and activating epidermal growth factor receptor (EGFR) mutations.Chemotherapy-naïve for NSCLC from China, Japan, Korea, Taiwan (35 sites) advanced, EGFR-mutant, NS were randomly assigned (2:1; computer-generated, interactive voice response) open-label (500 mg/m(2) on day 1 every 21-day cycle) plus...
Selpercatinib, a first-in-class, highly selective, and potent CNS-active RET kinase inhibitor, is currently approved for the treatment of patients with
Selpercatinib, a highly selective potent and brain-penetrant RET inhibitor, was shown to have efficacy in patients with advanced fusion–positive non–small-cell lung cancer (NSCLC) nonrandomized phase 1–2 study. Download PDF of the Research Summary. In randomized 3 trial, we evaluated safety first-line selpercatinib as compared control treatment that consisted platinum-based chemotherapy or without pembrolizumab at investigator's discretion. The primary end point progression-free survival...
Approximately 1-2% of non-small cell lung cancers (NSCLCs) are positive for rearranged during transfection (RET) gene fusions. The aim this real-world multi-national study was to describe clinical characteristics, biomarker testing, and treatment patterns patients with RET fusion-positive NSCLC. This observational conducted in 2020 nine countries using electronic patient record forms, following Adelphi Disease Specific Programme (DSP™) methodology. Patients advanced NSCLC (aNSCLC) were...
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned co-primary or secondary analyses are not yet available. Trial Updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported. Although CNS activity of selpercatinib patients with RET fusion-positive non–small cell lung cancer (NSCLC)...
IntroductionClinical studies have shown that a combination of tyrosine kinase inhibitor (TKI) and pemetrexed overcame acquired resistance to epidermal growth factor receptor (EGFR) TKI in NSCLC. Previously, pemetrexed+gefintib (P+G) had improved progression-free survival (PFS) compared with gefitinib. We present OS, updated PFS, biomarker analysis, safety P+G versus gefitinib.MethodsThis was phase 2, multicenter, randomized study conducted East Asian patients advanced nonsquamous NSCLC EGFR...
Spinal cord compression due to extramedullary hematopoiesis (EMH) is a rare complication of thalassemia and generally presents as paraparesis with sensory impairment. Complete paraplegia extremely in EMH although it known occur polycythemia vera sickle cell anemia. Treatment options mostly include surgery and/or radiotherapy. Whereas cases presenting have been treated either or radiotherapy equal frequency efficacy, almost all reported without radiation therapy. We hereby report case...
IntroductionThe primary analysis of this open-label, randomized, multicenter phase 3 study revealed no significant difference in progression-free survival between pemetrexed plus cisplatin followed by maintenance gefitinib (PC/G) and monotherapy (G) patients with advanced nonsquamous non–small cell lung cancer (NSCLC) unknown epidermal growth factor receptor gene (EGFR) mutation status; however, the hazard ratio favored PC/G. This report describes final overall (OS)...
Background : The therapeutic benefit of lycopene is well established for carcinoma prostate in various clinical trials and has been proposed other malignancies including high-grade gliomas. Setting Design Randomized placebo control study the Department Radiation Oncology a teaching hospital. Patients Methods Fifty patients with gliomas were treated surgery followed by adjuvant radiotherapy concomitant paclitaxel. randomized to receive either oral (Group A) 8 mg daily or B). Pre-and...
Pediatric glioblastoma (pGBM) patients are underrepresented in major trials for this disease. We aimed to explore the outcome of pGBM treated with concurrent and adjuvant temozolomide (TMZ).23 from 2004 2010 were included retrospective analysis. Adjuvant therapy conformal radiation 60 gray at 2 gray/fraction daily over 6 weeks TMZ 75 mg/m(2) followed by six cycles 150-200 (day 1-5) every 4 weeks. Kaplan-Meier estimates overall survival (OS) determined. Univariate analysis log-rank test was...
REVEL demonstrated improved overall survival (OS), progression-free (PFS), and objective response rate (ORR) with docetaxel+ramucirumab versus docetaxel+placebo in 1,253 intent-to-treat (ITT) stage IV non-small cell lung cancer patients disease progression following platinum-based chemotherapy. Results from the East Asian subgroup analysis are reported.Subgroup analyses were performed ITT population (n=89). Kaplan-Meier Cox proportional hazards regression for OS PFS, Cochran-Mantel-Haenszel...
Ectopic or accessory breast tissue is most commonly located in the axilla, though it may be present anywhere along milk line. Development hormone dependent, similar to normal tissue. These lesions do not warrant any intervention unless they produce discomfort, thus their identification and distinction from other pathologies, both benign malignant, essential. We report a case with locally advanced cancer who presented an ipsilateral axillary mass following surgery, radiotherapy, chemotherapy....